Original Publication Date: 1 March, 2014
Publication / Source: Journal of Comparative Effectiveness Research
Authors: Joshua A Roth, Mark E Bensink, Paul V O’Donnell et al.
Background: BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost–effectiveness analysis to be conducted alongside a BMT trial.